Member, Scientific Advisory Board

Professor Mike Waring

Mike Waring holds the Chair of Medicinal Chemistry in the School of Chemistry and the Northern Institute for Cancer Research at Newcastle University (2015 – present). Prior to joining Newcastle University, he worked as a medicinal chemist at AstraZeneca (2001-2015) where he became Principal Scientist. He has led medicinal chemistry in drug discovery programmes that have delivered 14 candidate drugs in the fields of cancer and diabetes, including the mutant EGFR inhibitor osimertinib that is now an approved drug for the treatment of lung cancer.

Mike is the author of more than 50 papers and patents that have received in excess of 1600 citations. His contributions to medicinal chemistry have been recognised by several awards including the 2010 Royal Society of Chemistry Capps Green Zomaya Memorial Medal and the 2014 Royal Society of Chemistry Biological and Medicinal Chemistry Sector Lectureship for outstanding contributions to medicinal chemistry.